DOI: https://doi.org/10.26641/2307-0404.2018.2(part1).129508

Changes of platelets activity in patient swith COPD and concomitant arterial hypertension under the influence of L-arginine.

О. М. Kovalenko

Abstract


Objective: to investigate the influence of L - arginine on platelets activity in patients with COPD and concomitant arterial hypertension. 30 patients with COPD of A - D category combined with hypertension (Н) I - II stage in the state of disease control were examined. In I gr. (n=20) patients received L – arginine (Tivortin) in a daily dose of 4g as additional medication to the basic therapy for 30 days. Patients of II gr. (n=10) received only basic therapy. The adhesion of platelets (pl), induced with adenosine diphosphate (ADP), collagen and thrombin (optical turbidometric aggregatometry method) were determined. Additionaly, in I gr. (n=6) there were determined the level of activated, aggregated, degranulated pl, packing density of pl granules (transmission electron microscopy). Under the influence of therapy in patients of I gr. degree of pl adhesion, degree of induced pl aggregation (collagen, thrombin), rate of aggregation (ADP, thrombin), activity of pl von Willebrandt factor activity (collagen, thrombin) decreased, level of activated, aggregated and degranulated pl decreased; packing density of α - granules increased (p<0.05). In II gr.of patients significant changes in the indices of adhesion and induced aggregation of pl were not detected. In comorbid patients with COPD and arterial hypertension L-arginine (Tivortin) reduces platelet activity and may reduce thrombogenic potential and risk of thrombotic events.


Keywords


СOPD; hypertension; adhesion of platelets; platelets aggregation; L-arginine

References


KovalenkoOM, RodIonova VV, Voronina NO. [Features of thrombocyte linkage of hemostasis in pa­tients with chronic obstructive pulmonary disease in combination with hypertension]. Medicni Perspektivi. 2017;3(1):28-33. Ukrainian.

Kozlovskii VN, Kovtun OM, Serouhova OP, Det­kovskaya IN. [Research methods and clinical value of aggregation of thrombocytes. Focus on the spontaneous aggregation]. Vestnik Vitebskogo Gosudarstvennogo Me­dicinskogo universiteta. 2013;4:79-91. Russian.

Dzyak GV, Pertseva TO, Kuz’mina AP, et al. [Practical skills on issues of hemostasiology: Teaching aid]. Dnipropetrovsk: IMA-pres. 2011;308. Russian.

Maclay JD, MacNee W. Cardiovascular Diseasein COPD. Chest. 2013;143:798-807.

Varga-Szabo D, Pleines I, Nieswandt B. Cellad hesion Mechanism sinpletelets. Arteriosclerosis, Throm­bosis, andVascularBiology. 2008;28:403-12.

Dercamer M, Yanssen W. Chronic obstructive pulmonary diseases and comorbidities. Lancet Respir Med. 2013;1.73-8.

Gimbrone M, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of atherosclerosis. Cir­culation Research. 2016;118:620-36.

Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the managemen to arterial hypertension: the Task Forcefor the management of arterial hypertension of the European Society of Hy­pertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertension. 2013;31:1281-357.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) The Global Strategy for tre Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2018 report). [Internet]. Available from: http://www.goldcopd.org

Chen W, Thomas J, Sadatsafavi M, Fitz Gerald JM. Risk of cardio vascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic revie wand meta-analysis. Lancet Respir Med; 2015. Available from: https://doi.org/10.1016/S2213-2600(15)00241-6

Tousoulis D, Kampoli AM, Tentolouris C, Papa­georgiou N, Stefanadis C. The Role of Nitric Oxide on Endothelial Function. Current Vascular Pharmacology. 2012;10:4-18.

World report on ageing and health [Internet]. World Health Organization. 2015. Available from: http://www.who.int/ageing/publications/world-report-2015/en/

Zhao Y, Vanhoutte P, Leung S. Vascular nit­ricoxid: Beyonde NOS. Journal of Pharmacological Sciences. 2015;129:83-94.


GOST Style Citations


  1. Коваленко О.М. Особливості тромбоцитарної ланки гемостазу у хворих з хронічним обструктивним захворюванням легенів у сполученні з гіпертонічною хворобою / О.М. Коваленко, В.В. Родіонова, Н.О. Во­роніна // Медичні перспективи. – 2017. – № 3 (1) – C. 28-33. http://medpers.dsma.dp.ua/issues/2017/N3part1/28-33.
  2. Методы исследования и клиническое значение агрегации тромбоцитов. Фокус на спонтанную агре­гацію / В.Н. Козловский, О.М. Ковтун, О.П. Серо­ухова, И.Н. Детковская [та ін.] // Вестник Витебск. гос. мед. ун-та. – 2013. – Т. 12, № 4. – С. 79-91. https://cyberleninka.ru/article/n/metody-issledovaniya-i-klinicheskoe-znachenie-agregatsii-trombotsitov-fokus-na-spontannuyu-agregatsiyu
  3. Практичні навички з питань гемостазіології: навч.-метод. посіб. / Г.В. Дзяк, Т.О. Перцева, А.П. Кузь­міна [та ін.]; за ред. Г.В. Дзяка. – Дніпропетровськ: ІМА-прес, 2011. – 308 с.
  4. Cardiovascular Disease in COPD / J.D. Maclay, W. MacNee // Chest– 2013. – Vol. 143, N 3. – P. 798-807. https://doi.org/10.1378/chest.12-0938
  5. Cellad hesion Mechanism sinpletelets / D. Varga-Szabo, I. Pleines, B. Nieswandt [ et al.] // Arteriosclerosis, Thrombosis, VascularBiology. – 2008. – Vol. 28. – P. 403-412. https://doi.org/10.1161/ATVBAHA.107.150474
  6. Chronic obstructive pulmonary diseases and co­mor­bidities / M. Dercamer,W. Yanssen // Lancet Respir Med. – 2013. – Vol. 1 – P. 73-78. https://doi.org/­10.1016/S2213-2600(12)70060-7
  7. Gimbrone M. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis / M. Gimbrone, G. García-Cardeña // Circulation Research. – 2016. – Vol. 118. – P. 620-636. ­https://doi.org/10.1161/CIRCRESA­HA.115.306301
  8. ESH/ESC Guide lines for the managemen tof arterial hypertension: the Task Forcefor the managemen to arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Car­diology (ESC) / G. Mancia, R. Fagard, K.Narkiewicz [et al.] // J. Hypertension. – 2013. – Vol. 31. – P. 1281-1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc
  9. Global Initiative for Chronic Obstructive Lung Disease (GOLD) The Global Strategy for tre Diagnosis, Management, and Prevention of Chronic Obstructive Pul­monary Disease (2018 report) http://www.goldcopd.org.
  10. Risk of cardio vascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic revie wand meta-analysis / W. Chen, J. Thomas, M. Sa­datsafavi, JM. FitzGerald // Lancet Resp. Med. – 2015. https://doi.org/10.1016/S2213-2600(15)00241-6
  11. The Role of Nitric Oxideon Endothelial Function / D. Tousoulis, A.M. Kampoli, C. Tentolouris, N. Papa­georgiou [et al.] // Current Vascular Pharmacology. – 2012. – Vol. 10. – P. 4 – 18. https://doi.org/10.2174/­157016112798829760
  12. World report on ageing and health [Електронний ресурс] // World Health Organization. – 2015. http://www.who.int/ageing/publications/world-report-2015/en/.
  13. Zhao Yingzi. Vascularnitricoxid: Beyonde NOS/ Yingzi Zhao, Paul M. Vanhoutte, Susan W.S. Leung // J. Pharmacol. Sciences. – 2015. – Vol. 129. – P. 83-94. https://doi.org/10.1016/j.jphs.2015.09.002